Safety and efficacy of AAV8-aflibercept in treating choroidal neovascularization via single-cell RNA sequencing.

Jiemei Shi, Kaicheng Wu, Lihui Chen, Yinling Li, Chunhui Jiang

Abstract read

In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiemei ShiDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai 200031, China.

Kaicheng WuDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai 200031, China.

Lihui ChenShanghai Correge Pharmaceutical Technology Co., Ltd, Shanghai, China.

Yinling LiShanghai Correge Pharmaceutical Technology Co., Ltd, Shanghai, China.

Chunhui JiangDepartment of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai 200031, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluated the efficacy and safety of adeno-associated virus serotype 8 (AAV8)-aflibercept for treating choroidal neovascularization (CNV) in mice model, utilizing single-cell RNA sequencing (scRNA-seq) to investigate retinal effects. AAV8-aflibercept was administered via subretinal injection to mice, followed by laser-induced CNV modeling. Successful expression was achieved following subretinal injection of AAV8-aflibercept, aflibercept protein expression showed a gradual decline after peaking at week 4, but remained at relatively stable levels through weeks 8-24. The therapeutic effect was assessed using fluorescein angiography and quantified. AAV8-aflibercept significantly decreased CNV areas across dosages from 3 × 10

Indexed as

adeno-associated virusafliberceptchoroidal neovascularizationefficacysafetysingle-cell RNA sequencing

Identifiers

PMID41399432

DOI10.1016/j.omtm.2025.101625

PMCPMC12702363

What Socratic holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.